During the past decade, Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital" #1 sponsor was "Seagen Inc." with 2 trials, followed by "BeiGene" with 1 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 1 trials sponsored, "Fang Jun" with 1 trials sponsored and "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital" #1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital" are "Advanced Solid Tumor" (1 trials), "Bronchoesophageal Fistula" (1 trials), "Endobronchial Metastases" (1 trials), "Epithelial Ovarian Cancer" (1 trials) and "Fallopian Tube Cancer" (1 trials). Many other conditions were trialed in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Propofol" (2 trials), "1.Experimental: A (Part 1): Fluzoparib and SHR -1316" (1 trials), "2.Experimental: B (Part 1): Fluzoparib and SHR -1316" (1 trials), "3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion" (1 trials) and "Combination product: Trastuzumab + Pertuzumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".